Allergy Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Allergy Therapeutics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

Allergy Therapeutics: 12 sponsored US clinical trials, none currently recruiting.

Allergy Therapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 3 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type I Hypersensitivity, with 2 trials.

Top-decile sponsor footprint

Allergy Therapeutics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

11 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 1

Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects

NCT05476497
COMPLETED Phase 3

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

NCT05540717
COMPLETED Phase 2

An Exploratory Study of PQ Grass 27600 SU

NCT04687059
COMPLETED Phase 1

A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL

NCT03931993
COMPLETED Phase 2

Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

NCT02582073
COMPLETED Phase 1

A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL

NCT02557633
COMPLETED Phase 3

Efficacy and Safety/Tolerability of Ragweed MATA MPL

NCT00423787
COMPLETED Phase 3

Efficacy and Safety/Tolerability of Grass MATA MPL

NCT00414141
COMPLETED Phase 2

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

NCT00258635
COMPLETED Phase 2

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

NCT00113750
COMPLETED Phase 1

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

NCT00104390
COMPLETED Phase 2

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

NCT00104377

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 5
Phase 3 3

Therapeutic Areas

Type I Hypersensitivity 2
Seasonal Allergic Rhinitis 1
Peanut Allergy 1

How the Allergy Therapeutics early-phase archive is shaped

12 indexed studies, none listed as recruiting (0% open); 11 completed (92%).

Phase mix: 3 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Type I Hypersensitivity (2 trials), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Allergy Therapeutics: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Allergy Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Allergy TherapeuticsAlachua Government ServicesAmpio Pharmaceuticals.AngiodynamicsApnimed10xBio22nd Century Group23andMe3-C Institute for Social Development
Allergy Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Allergy Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Allergy Therapeutics page

12 registered trials is a research-attention snapshot, not an endorsement of Allergy Therapeutics or any single study.

  • None of Allergy Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Type I Hypersensitivity is the condition Allergy Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type I Hypersensitivity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Allergy Therapeutics pipeline card: 12 registered trials from official public datasets.Report a data error.